Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs
Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors and ITI-333 platforms
Webcast scheduled for Wednesday, Oct. 20 from 12:30 to 3:30 p.m. ET
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a virtual event to discuss the Company’s robust pipeline including lumateperone, ITI-1284, PDE inhibitor platform and ITI-333. The virtual event will take place on Wednesday, October 20, 2021, beginning at 12:30 p.m. ET. and will feature presentations and discussion from the Company’s management team and external key opinion leaders.
The live and archived webcast can be accessed under "Events & Presentations" on the Investor Relations section of the Company's website at Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit .
Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Lisa Burns
212-213-0006
MEDIA INQUIRIES:
Sara Franks
Corporate Media Relations W2O Group
410-991-4287
